ReviewJournal of blood medicine2022

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.

Samantha PascaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.